LRP1B can activate multiple carcinogenic pathways and enhance cellular activity, potentially contributing to the poor prognosis observed in hepatocellular carcinoma, non-small cell lung cancer, ovarian clear cell carcinoma, and other tumors [37, 38]. Here, LRP1B is linked to non-small cell lung carcinoma.